In this photo illustration, the UK pharmaceutical multinational company GlaxoSmithKline (GSK) logo is displayed on a smartphone with a computer model of the COVID-19 coronavirus in the background.
Budrul Chukrut | SOPA pictures | Getty Images
The FDA filing is based on an interim analysis of a Phase 3 study evaluating the drug for the early treatment of Covid-19 in adults at high hospital risk. The drug reduced hospital stays or death from Covid-19 by 85% compared to a placebo.
The two companies in August started testing the antibody on early-stage Covid-19 patients in hopes of preventing symptoms from getting worse.
This is a developing story. Please try again.
-Reuter contributed to this report.